Figure 6.
Figure 6. Graphical and schematic summaries of immune landscapes in DLBCLs with and without PD-L1 gene alterations. (A) Summary radar plot (left), with 20% radial intervals depicting 7 parameters that characterize the immunogenomic landscape of PD-L1 gene–altered vs unaltered subsets. Indices were normalized from 0 to 1; bold connecting lines represent average scores for PD-L1–altered (red) vs PD-L1–unaltered (blue) subsets. Curves for individual patients are represented as gray lines (left) or in individual radar plots (right), colored by PD-L1–altered (red) or PD-L1–unaltered (blue) status. (B) Schematic representation of the immunogenomic landscapes of PD-L1 altered DLBCLs. PD-L1 gene–altered DLBCLs are characterized by frequent loss-of-function mutations in TNFAIP3 (A20) and increased NF-κB pathway activation. As a result, these lymphomas demonstrate evidence of enhanced immune surveillance, including robust infiltration by clonally restricted T cells. In addition to marked upregulation of PD-L1 protein on the lymphoma cell surface, PD-L1 gene–altered DLBCLs also commonly downregulate HLA I and II expression and harbor loss-of-function mutations in other genes critical for maintaining tumor immune surveillance.

Graphical and schematic summaries of immune landscapes in DLBCLs with and without PD-L1 gene alterations. (A) Summary radar plot (left), with 20% radial intervals depicting 7 parameters that characterize the immunogenomic landscape of PD-L1 gene–altered vs unaltered subsets. Indices were normalized from 0 to 1; bold connecting lines represent average scores for PD-L1–altered (red) vs PD-L1–unaltered (blue) subsets. Curves for individual patients are represented as gray lines (left) or in individual radar plots (right), colored by PD-L1–altered (red) or PD-L1–unaltered (blue) status. (B) Schematic representation of the immunogenomic landscapes of PD-L1 altered DLBCLs. PD-L1 gene–altered DLBCLs are characterized by frequent loss-of-function mutations in TNFAIP3 (A20) and increased NF-κB pathway activation. As a result, these lymphomas demonstrate evidence of enhanced immune surveillance, including robust infiltration by clonally restricted T cells. In addition to marked upregulation of PD-L1 protein on the lymphoma cell surface, PD-L1 gene–altered DLBCLs also commonly downregulate HLA I and II expression and harbor loss-of-function mutations in other genes critical for maintaining tumor immune surveillance.

Close Modal

or Create an Account

Close Modal
Close Modal